---
title: Data Integrity Compliance for Pharma: A Practical Playbook
date: 2026-08-10
description: Ensure your pharmaceutical data integrity compliance with key strategies for validated systems, audit trails, and risk controls. Start today!
author: Qualitum
cover: https://csuxjmfbwmkxiegfpljm.supabase.co/storage/v1/object/public/blog-images/organization-48457/1786130277523_Gloved-hand-inspecting-pharma-control-panel.jpeg
coverAlt: Gloved hand inspecting pharma control panel
---

Achieving data integrity compliance requires four immediate deliverables: demonstrably ALCOA+ records across every CGMP workflow, validated computerized systems with secure and reviewable audit trails, risk-based controls prioritized using ICH Q9 principles, and documented governance with active CAPA processes. Start here:

- **Map your data inventory.** Identify every system, paper record, and hybrid handoff where CGMP data is created, transformed, stored, or archived. Assign a criticality tier to each.
- **Prioritize CSV for high-critical systems.** Validated CGMP workflows are non-negotiable. Begin with systems that directly affect product release decisions.
- **Enforce unique user IDs and MFA.** Shared logins are among the most cited inspection findings. Eliminate them before the next audit cycle.
- **Verify audit trails are immutable and reviewed.** Audit trails must be time-stamped, non-editable, and subject to a documented review process according to risk.
- **Document SOPs and training records.** A policy that exists only in practice is not defensible. Written procedures and training evidence are required artifacts.
- **Implement risk-based monitoring and CAPA.** Monitoring frequency should reflect data criticality; every integrity event needs a documented investigation and corrective action.

**Assign in the next 7–30 days:** (1) Task your QA lead to produce a data inventory with criticality tiers within 30 days. (2) Direct IT and Validation to audit trail configurations on your top five CGMP systems within 14 days. (3) Have your Compliance Officer confirm that all CGMP system users have individual, traceable credentials within 7 days.

***

## Key Takeaways

Data integrity compliance in pharma requires a documented data inventory with criticality tiers, validated CGMP systems with immutable audit trails, and a governance program with active monitoring and CAPA, all aligned to ALCOA+ and FDA expectations.

| Point | Details |
|---|---|
| Start with a data inventory | Map every CGMP data source, assign criticality tiers, and produce a DIRA before prioritizing any remediation. |
| Validate high-critical systems first | CSV for systems that directly affect product release is the highest-priority technical control. |
| Governance requires written policy | A data governance policy with named owners and a minimum SOP set is a required inspection artifact, not a best practice. |
| Monitoring must be continuous | Audit trail review frequency, backup/restore testing, and internal audits should be scheduled and risk-tiered, not event-driven. |
| Qualitum enforces ALCOA+ at write-time | Qualitum's agentic platform generates audit-ready validation evidence with built-in ALCOA+ checks, reducing CSV cycle time significantly in authoring. |

***

## Table of Contents

- [What does FDA actually require for data integrity compliance?](#what-does-fda-actually-require-for-data-integrity-compliance)
- [ALCOA+ explained: what each principle requires in practice](#alcoa-explained-what-each-principle-requires-in-practice)
- [How to map data lifecycles and assess criticality](#how-to-map-data-lifecycles-and-assess-criticality)
- [What does good computerized system validation look like?](#what-does-good-computerized-system-validation-look-like)
- [Governance, roles, and training: building a defensible program](#governance-roles-and-training-building-a-defensible-program)
- [How to detect integrity failures and document CAPA](#how-to-detect-integrity-failures-and-document-capa)
- [How to stay audit-ready: monitoring and internal audits](#how-to-stay-audit-ready-monitoring-and-internal-audits)
- [Common failure modes and their regulatory consequences](#common-failure-modes-and-their-regulatory-consequences)
- [Phased implementation checklist and timeline](#phased-implementation-checklist-and-timeline)
- [How automation reduces the burden of validation and audit evidence](#how-automation-reduces-the-burden-of-validation-and-audit-evidence)
- [What most data integrity programs get wrong](#what-most-data-integrity-programs-get-wrong)
- [Qualitum: built for the compliance burden this playbook describes](#qualitum-built-for-the-compliance-burden-this-playbook-describes)
- [Sources](#sources)
- [FAQ](#faq)

## What does FDA actually require for data integrity compliance?

[FDA guidance](https://www.fda.gov/media/119267/download) is unambiguous: all CGMP data must be reliable and accurate, audit trails must permit reconstruction of events, and any invalidated result must remain part of the record with documented justification. These are not aspirational standards. They are the basis for warning letters, import alerts, and consent decrees.

The primary regulatory documents every pharma and biotech compliance team must know:

- **[21 CFR Part 211](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211)** — CGMP regulations for finished pharmaceuticals. Specifies recordkeeping, backup requirements (backup data must be exact, complete, and secure from alteration), and inspection access obligations.
- **FDA Data Integrity and Compliance With Drug CGMP Guidance** — defines audit trail expectations, HPLC metadata examples, and the requirement that CGMP workflows be validated commensurate with risk.
- **[FDA Guidance on Investigating Out-of-Specification Results](https://www.fda.gov/downloads/drugs/guidances/ucm495891.pdf)** — requires scientifically sound investigations, risk-based remediation, and retention of original data alongside investigation reports.
- **21 CFR §§ 210, 211, 212** — the underlying CGMP regulations that FDA inspectors cite when issuing observations.

> **Regulatory quick facts:** FDA warning letters for data integrity failures commonly cite shared login credentials, deleted or altered audit-trail entries, unvalidated CGMP software, and failure to investigate out-of-specification results. Consequences range from Form 483 observations to consent decrees that halt manufacturing. FDA expects remediation to be risk-based, documented, and verified, not simply a policy update.

***

## ALCOA+ explained: what each principle requires in practice

ALCOA+ is the organizing framework for pharma data integrity. The original five principles (Attributable, Legible, Contemporaneous, Original, Accurate) were extended to ALCOA+ with four additional attributes: Complete, Consistent, Enduring, and Available. Together they define what a trustworthy CGMP record looks like.

| ALCOA+ Element | Definition | Practical Control | Pharma Example | Common Red Flag |
|---|---|---|---|---|
| Attributable | Record identifies who performed the action and when | Unique user IDs, electronic signatures, no shared accounts | HPLC injection linked to analyst login | Shared "admin" account used for injections |
| Legible | Record is readable for its full retention period | Durable ink, non-editable electronic records, legible printouts | Batch record entries in permanent ink | Pencil entries, overwritten values without single strikethrough |
| Contemporaneous | Recorded at the time of the activity | System timestamps, no pre- or post-dating | Weighing recorded at time of dispensing | Backdated entries, bulk data entry at end of shift |
| Original | First capture of data; no transcription without traceability | Raw data retained; electronic originals preserved | Chromatography raw data file, not just the report | Printing and discarding electronic originals |
| Accurate | Correct and truthful | Calibrated instruments, validated calculations | Balance printout attached to batch record | Manual transcription errors, rounded values |
| Complete | All data including invalidated results retained | Full audit trail; no selective deletion | OOS result retained with investigation | Missing integration events, deleted injections |
| Consistent | Dates, times, and sequences are internally coherent | Synchronized system clocks, NTP servers | Timestamps across LIMS and MES agree | Time-zone mismatches, sequence gaps |
| Enduring | Record survives for its required retention period | Validated backup, media migration plan | Electronic records on validated archive server | Records on unsupported media, no restore testing |
| Available | Accessible for review and inspection | Indexed archive, access controls, disaster recovery | Inspector can retrieve a batch record within hours | Archive system decommissioned, no retrieval procedure |

WHO/PIC/S Annex 4 endorses ALCOA+ as the standard and requires that controls be embedded in the pharmaceutical quality system, not bolted on as a separate program.

***

## How to map data lifecycles and assess criticality

The required deliverable is a documented data inventory with criticality tiers and mapped data flows. Without it, you cannot prioritize remediation, justify control selection, or demonstrate a risk-based approach to an inspector.

1. **Identify every data-generating node.** List all systems (LIMS, MES, ERP, chromatography data systems, environmental monitoring), paper records, and hybrid handoffs. Include cloud vendors and contract laboratory interfaces.
2. **Document the data flow for each node.** Capture: where data is created, how it is transformed or transcribed, where it is stored and backed up, how long it is retained, and how it is eventually archived or destroyed.
3. **Capture metadata at each node.** For each system, record: data owner, system owner, user access model, audit trail status, backup frequency, and last restore test date.
4. **Assign a criticality tier.** Use an ICH Q9-aligned scoring model: severity (impact on product quality or patient safety if data is wrong), occurrence (likelihood of error or manipulation), and detectability (how quickly a failure would be found). [APIC's practical guide](https://apic.cefic.org/wp-content/uploads/2022/07/Data-Integrity-Best-Practices-Guide-for-API-Rev-2-Final-April-2022.pdf) recommends a low/medium/high system categorization with defined controls per tier.
5. **Document the Data Integrity Risk Assessment (DIRA).** The DIRA is the formal output. It ties each system to its criticality tier, the controls in place, identified gaps, and the remediation priority.
6. **Assign owners and remediation timelines.** Every gap in the DIRA needs an owner, a target date, and an interim control if full remediation will take more than 30 days.

**Pro Tip:** *Automate metadata capture at the point of data creation wherever possible. Systems that log user, timestamp, instrument ID, and parameter values automatically at write-time eliminate the most common attribution gaps before they become inspection findings. Platforms like Qualitum's [Risk·AI](https://qualitum.ai/platform/risk-ai) enforce this at the record level, reducing the manual effort of post-hoc metadata reconstruction.*

Multi-site operations add complexity. Coordinating data flows across sites and external partners requires clear data transfer agreements and verified chain-of-custody documentation. Resources on [coordinating multi-site diagnostic research data](https://blog.kohealthlabs.com/blog/how-to-coordinate-multi-site-diagnostic-research-data) illustrate how metadata integrity must be preserved across every transfer point, not just at the originating system.

***

## What does good computerized system validation look like?

The immediate CSV deliverable is validated CGMP workflows with documented evidence of correct functionality, secure audit trails, and preserved metadata sufficient for reconstruction. Validation scope is risk-based: systems that directly affect product release or patient safety require the most rigorous evidence.

**CSV checklist:**

1. User Requirements Specification (URS) — defines what the system must do for CGMP purposes
2. Risk analysis — identifies functions requiring validation and sets the validation strategy
3. Installation Qualification (IQ) — confirms the system is installed as specified
4. Operational Qualification (OQ) — verifies the system operates within defined parameters
5. Performance Qualification (PQ) — confirms the system performs correctly in the actual use environment
6. Workflow validation — tests CGMP-specific workflows end-to-end, including error handling and access controls

When a system mixes CGMP and non-CGMP functions, validate only the CGMP-relevant functions, but document the boundary clearly. Inspectors will ask.

**Audit trail and metadata requirements:**

- Audit trails must be computer-generated, time-stamped, and non-editable by any user including administrators.
- Every audit trail entry must capture: user identity, date and time, action performed, and the original and new value for any changed field.
- Audit trails must be reviewed periodically, with review frequency tied to data criticality. High-critical systems warrant more frequent review.
- Metadata (instrument ID, method version, analyst, sequence file) must be preserved with the raw data file, not just the final report.

**Inspection evidence inspectors expect:**

- Validation master plan or equivalent governing document
- Completed IQ/OQ/PQ protocols with executed test results and deviations noted
- Audit trail configuration screenshots and access control matrix
- Periodic audit trail review records
- Backup and restore test records

[FDA guidance on CGMP computerized systems](https://www.fda.gov/RegulatoryInformation/Guidances/ucm125067.htm) explicitly links audit trail content requirements to CGMP obligations and confirms that CGMP workflows must be validated commensurate with risk.

***

## Governance, roles, and training: building a defensible program

Senior management accountability and a written data governance policy are required, not optional. An inspector who finds no documented ownership of data integrity at the executive level will treat that as a systemic finding.

**Minimum SOP set:**

- Data governance policy (scope, principles, management accountability)
- Data lifecycle procedures (creation, review, approval, retention, disposal)
- Access control and user management
- Audit trail review procedure (frequency, reviewer role, escalation)
- Change control for CGMP systems
- Record retention and disposal (including media sanitization per applicable standards)
- Vendor and contract laboratory management
- Incident investigation and CAPA for data integrity events

**Roles and responsibilities:**

- **Data owner:** Accountable for the integrity of data within their process area; approves access, reviews audit trails, escalates anomalies.
- **QA:** Provides oversight, approves SOPs, reviews CAPA, and signs off on periodic audit trail reviews.
- **Validation/IT:** Maintains validated state of CGMP systems, manages access controls, conducts backup/restore testing.
- **Operations:** Follows procedures, reports anomalies, participates in training.

Training must be documented, role-specific, and repeated at a defined cadence. Annual refreshers are a floor, not a ceiling. New-hire training before system access is non-negotiable. Training records must be retained and available for inspection.

Culture matters as much as documentation. When personnel feel pressure to meet timelines at the expense of data integrity, falsification risk rises. PI 041-1 guidance emphasizes that organizational controls, including open reporting channels and management tone, are as important as technical controls. Make it easier to report a problem than to hide one.

***

## How to detect integrity failures and document CAPA

When a data integrity event occurs, the investigation workflow determines whether your response is credible to a regulator. The sequence matters.

1. **Scope the event.** Define what data, systems, and time periods are potentially affected.
2. **Contain the risk.** Restrict access if manipulation is ongoing; preserve originals immediately.
3. **Collect evidence.** Retrieve audit trail exports, backup copies, instrument logs, and any paper records. Do not alter anything.
4. **Determine root cause.** Distinguish between systemic failures (inadequate controls, training gaps) and isolated human errors. Both require documented analysis.
5. **Assess impact.** Determine whether affected data influenced any released product, regulatory submission, or patient safety decision.
6. **Implement corrective and preventive actions.** Address both the immediate failure and the systemic condition that allowed it.
7. **Verify effectiveness.** Confirm that corrective actions actually prevent recurrence before closing the CAPA.

**CAPA documentation template:**

| Field | Required Content |
|---|---|
| Event description | What happened, when, and which systems/records are involved |
| Impact assessment | Products, batches, submissions, or decisions potentially affected |
| Root cause | Documented analysis (5-Why, fishbone, or equivalent) |
| Corrective action | Specific steps taken to fix the immediate failure, with owner and completion date |
| Preventive action | Systemic changes to prevent recurrence, with owner and target date |
| Verification | Evidence that actions were completed and effective, with reviewer sign-off |

FDA guidance on out-of-specification investigations requires that original data be retained alongside the investigation report and justification. Invalidated results must remain in the record set. Deleting them, even with good intent, is itself a data integrity violation.

When the impact assessment reveals that released product or a regulatory submission may be affected, consult your regulatory affairs team immediately. Voluntary disclosure timelines vary by jurisdiction and submission type.

***

## How to stay audit-ready: monitoring and internal audits

The monitoring outcome you need is continuous visibility on data-critical systems, with risk-based review triggers and a scheduled internal audit program. Audit-readiness is not a fire drill before an inspection. It is a steady operational state.

**Monitoring metrics to track:**

- Audit trail review completion rate (by system and review period)
- Failed integrity checks or hash verification failures on archived records
- Unauthorized access attempts or privilege escalation events
- Backup success rate and restore test pass rate
- Open data integrity CAPAs by age and criticality
- Training completion rate for data integrity SOPs

**Audit cadence guidance:**

- High-critical systems: audit trail review at least quarterly; internal system audit annually or after significant change.
- Medium-critical systems: audit trail review semi-annually; internal audit every 18 months.
- Low-critical systems: annual audit trail review; audit on a risk-triggered basis.

Internal audits should be conducted by personnel independent of the area being audited. Findings must be documented, assigned to owners, and tracked to closure. QA signs off on audit reports and CAPA completion.

The APIC practical guide recommends mandatory backup/restore testing and archive integrity verification as standing controls, not one-time events. Schedule them on a calendar, not a "when we get to it" basis.

***

## Common failure modes and their regulatory consequences

The most frequently cited data integrity failures share a pattern: inadequate technical controls that made falsification easy, combined with insufficient oversight that allowed it to continue undetected.

**Most common failure modes:**

- Shared login credentials across multiple analysts
- Deleted or overwritten audit trail entries
- Undocumented reprocessing of chromatography data to achieve passing results
- Unvalidated spreadsheets used for CGMP calculations
- Backup systems that have never been tested for successful restoration
- Paper records completed in pencil or with correction fluid

**Anonymized case examples:**

**Case A — Chromatography reprocessing.** A quality event review revealed that analysts at a contract manufacturing site had reprocessed HPLC injections multiple times, retaining only the passing result. The original injections were not deleted but were excluded from the batch record. Detection came during a routine internal audit of the chromatography data system. The regulatory consequence was a Form 483 observation and a required CAPA that included revalidation of the CDS, retraining of all analysts, and retrospective review of 18 months of batch records.

**Case B — Shared administrator account.** During an FDA inspection, investigators found that multiple personnel used a single administrator account for a manufacturing execution system. Attribution of individual actions was impossible. The finding escalated to a warning letter. Remediation required individual account creation, a full access control audit, and a documented investigation into whether any CGMP decisions made under the shared account were reliable.

**Case C — Unvalidated calculation spreadsheet.** A site used an Excel spreadsheet for yield calculations without a validation protocol. An error in a formula had been present for over a year. The spreadsheet was not version-controlled and had no audit trail. Remediation required retrospective impact assessment of all affected batches, a validated replacement tool, and a change control procedure for CGMP spreadsheets.

***

## Phased implementation checklist and timeline

A phased approach lets you contain the highest risks quickly while building the governance infrastructure that sustains compliance long-term.

**Phase 0: Discovery (Weeks 1–4)**

1. Conduct data inventory and produce the DIRA with criticality tiers.
2. Identify the top five highest-risk CGMP systems for immediate attention.
3. Audit user account configurations on all CGMP systems; document shared accounts.
4. Confirm backup and restore procedures exist and have been tested.

**Phase 1: Containment and high-risk CSV (Weeks 4–12)**

1. Eliminate shared accounts; assign individual credentials with MFA.
2. Validate or revalidate the top five high-critical CGMP systems.
3. Enable and configure audit trails on all CGMP systems where not already active.
4. Implement interim controls (manual logs, dual review) for any system that cannot be immediately validated.

**Phase 2: Policy, SOP, and training (Weeks 8–20)**

1. Draft and approve the data governance policy and minimum SOP set.
2. Deliver role-specific training; document completion.
3. Establish the audit trail review schedule and assign reviewers.
4. Stand up the CAPA tracking process for data integrity events.

**Phase 3: Full remediation and verification (Months 4–9)**

1. Complete CSV for all remaining CGMP systems per the DIRA priority order.
2. Close all Phase 0/1 CAPAs with verified effectiveness evidence.
3. Conduct the first internal data integrity audit across all sites.
4. Verify that backup/restore tests are scheduled and passing.

**Phase 4: Sustainment (Month 9 onward)**

1. Embed monitoring metrics into the quality management review cycle.
2. Schedule recurring internal audits per the risk-based cadence.
3. Review and update the DIRA annually or after significant system changes.
4. Maintain training currency and update SOPs when regulatory guidance changes.

**Pro Tip:** *Use interim controls deliberately. When a system cannot be fully validated within the Phase 1 window, document the interim control (e.g., paper-based dual verification of outputs), set a firm remediation deadline, and track it as an open CAPA item. An undocumented interim control is indistinguishable from no control at all during an inspection.*

***

## How automation reduces the burden of validation and audit evidence

Organizations that apply automation to validation and metadata capture consistently see three measurable outcomes: shorter CSV cycles, more consistent audit evidence, and fewer manual documentation errors. The quiet tax of manual validation, hours spent authoring protocols, chasing signatures, and reconstructing metadata after the fact, is the largest avoidable cost in a pharma compliance program.

Qualitum's [agentic validation platform](https://qualitum.ai/platform/operate-ai) addresses this directly. Every record is ALCOA+ checked at write-time and review-time, which means attribution, timestamp, and completeness gaps are caught before they become inspection findings rather than after.

**Platform capabilities relevant to data integrity:**

- Automated, agent-authored validation evidence (URS, FS, DQ, IQ, OQ, PQ, CSV/CSA) with built-in ALCOA+ enforcement
- Immutable traceability matrix linking requirements to test evidence in real time
- Audit-ready documentation generated at the point of authoring, not assembled retrospectively
- Deviation and CAPA handling integrated into the validation lifecycle
- Validated private deployment with documented data residency controls

**Integration considerations:**

- Vendor qualification: confirm the platform has a validated deployment model and can provide the IQ/OQ evidence your team needs for its own CSV.
- QMS and LIMS connectivity: Qualitum integrates with major quality management systems, reducing duplicate data entry and preserving traceability across the quality ecosystem.
- Data residency: for organizations with US-only data requirements, confirm deployment options with Qualitum's [security and privacy documentation](https://qualitum.ai/security).

For regulated environments where multi-site data flows add complexity, [integrated clinical diagnostics platforms](https://kohealthlabs.com/data-ai) that automate metadata capture at the point of data generation offer a complementary approach to preserving attribution across CRO and partner networks.

**Pro Tip:** *When evaluating any validation automation tool, ask the vendor for their own IQ/OQ documentation and a sample of the ALCOA+ evidence their platform generates. A vendor that cannot produce inspection-ready evidence for their own system is unlikely to produce it for yours.*

> Qualitum's platform enforces ALCOA+ at write-time, which means the most common attribution and completeness gaps are closed before a record is ever submitted for review, not discovered during an audit.

***

## What most data integrity programs get wrong

The conventional advice on pharma data integrity focuses almost entirely on technical controls: enable audit trails, validate your systems, enforce unique logins. That advice is correct, but it addresses only half the problem.

The programs that fail inspection, or worse, produce a consent decree, almost always have the technical controls in place on paper. What they lack is a functioning governance layer. Audit trails are enabled but never reviewed. SOPs exist but training records are incomplete. CAPAs are opened but never verified for effectiveness. The documentation looks right; the practice does not match it.

There is also a persistent misunderstanding about the DIRA. Many organizations treat it as a one-time exercise, something to produce for an inspection and then file away. Regulators, including FDA and the WHO/PIC/S framework, expect it to be a living document that drives control selection, review frequency, and remediation priority on an ongoing basis. A DIRA that was last updated three years ago is not evidence of a risk-based program. It is evidence that the program stopped.

The other underrated risk is the hybrid environment. Most pharma sites run a mix of validated electronic systems, legacy paper records, and informal spreadsheets that have accumulated over years. The spreadsheets are where the most dangerous gaps hide, because they are often used for CGMP calculations without validation, version control, or audit trails. Regulators know this. The DIRA must capture every data-generating node, including the ones that feel too small to matter.

Automation changes the calculus here in a meaningful way. When validation evidence is generated by an agentic system that enforces ALCOA+ at write-time, the gap between what the SOP says and what the record shows closes automatically. That is not a marginal improvement. For organizations managing dozens of validated systems across multiple sites, it is the difference between a sustainable compliance program and a perpetual remediation cycle.

***

## Qualitum: built for the compliance burden this playbook describes

Validation teams at pharma and biotech organizations spend a disproportionate share of their time on documentation that should be generated automatically: authoring protocols, assembling traceability matrices, chasing signatures, and reconstructing audit evidence after the fact. Qualitum was built specifically to eliminate that burden.

![Qualitum](https://csuxjmfbwmkxiegfpljm.supabase.co/storage/v1/object/public/blog-images/organization-48457/1785522367413_qualitum.jpg)

The [Qualitum platform](https://qualitum.ai) uses agentic AI to author validation lifecycle documentation (URS, IQ/OQ/PQ, CSV/CSA, cleaning and sterilization protocols, risk assessments) with every record ALCOA+ checked at write-time. The result is audit-ready evidence generated at the point of authoring, not assembled under pressure before an inspection.

For organizations ready to move from reactive remediation to a proactive, continuously compliant validation program, the practical next step is a working session with the Qualitum team. [Book a session](https://qualitum.ai/book) to see how the platform maps to your current CGMP systems and validation backlog.

***

This article is general information, not a substitute for advice from a qualified lawyer. Consult a qualified legal professional about your own circumstances before acting on anything here.

## Sources

Primary regulatory and guidance documents for US-focused pharma data integrity compliance:

- [Fda](https://www.fda.gov/media/119267/download)
- [Accessdata](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211)
- [Fda](https://www.fda.gov/downloads/drugs/guidances/ucm495891.pdf)

***

## FAQ

### What are the ALCOA+ principles in pharma?

ALCOA+ stands for Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available. These nine attributes define what a trustworthy CGMP record must demonstrate to satisfy FDA and international regulatory expectations.

### What is a Data Integrity Risk Assessment (DIRA)?

A DIRA is a documented evaluation of every CGMP data source, scored by severity, occurrence, and detectability, that assigns a criticality tier to each system and drives control selection, audit trail review frequency, and remediation priority. WHO/PIC/S Annex 4 recommends it as a core governance tool.

### Can you give an example of data integrity compliance in practice?

A site that assigns unique user IDs to every CGMP system user, enables time-stamped and non-editable audit trails, reviews those audit trails quarterly for high-critical systems, and retains all original data including invalidated results with documented justification is demonstrating data integrity compliance in practice.

### What CGMP records must be validated and retained?

Any computerized system used to create, modify, maintain, archive, retrieve, or transmit CGMP data must be validated commensurate with risk under applicable CGMP regulations. Records must be retained as original or accurate reproductions, with backup copies that are exact, complete, and secure from alteration.

### How does Qualitum support data integrity compliance?

Qualitum enforces ALCOA+ at write-time across all validation lifecycle documents, generates immutable traceability matrices, and produces audit-ready evidence that reduces CSV cycle time. Its [Validate·AI platform](https://qualitum.ai/platform/validate-ai) integrates with existing QMS environments and supports validated private deployment for organizations with strict data residency requirements.

## Recommended

- [How to Test Data Integrity: A Practitioner's Guide · Qualitum blog](https://blog.qualitum.ai/test-data-integrity)
- [Platform · Qualitum](https://qualitum.ai/platform)
- [Operate·AI · Qualitum](https://qualitum.ai/platform/operate-ai)
- [Qualitum · The agentic validation platform for life sciences](https://qualitum.ai)

## FAQ
### What are the ALCOA+ principles in pharma?
ALCOA+ stands for Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available. These nine attributes define what a trustworthy CGMP record must demonstrate to satisfy FDA and international regulatory expectations.

### What is a Data Integrity Risk Assessment (DIRA)?
A DIRA is a documented evaluation of every CGMP data source, scored by severity, occurrence, and detectability, that assigns a criticality tier to each system and drives control selection, audit trail review frequency, and remediation priority. WHO/PIC/S Annex 4 recommends it as a core governance tool.

### Can you give an example of data integrity compliance in practice?
A site that assigns unique user IDs to every CGMP system user, enables time-stamped and non-editable audit trails, reviews those audit trails quarterly for high-critical systems, and retains all original data including invalidated results with documented justification is demonstrating data integrity compliance in practice.

### What CGMP records must be validated and retained?
Any computerized system used to create, modify, maintain, archive, retrieve, or transmit CGMP data must be validated commensurate with risk under applicable CGMP regulations. Records must be retained as original or accurate reproductions, with backup copies that are exact, complete, and secure from alteration.

### How does Qualitum support data integrity compliance?
Qualitum enforces ALCOA+ at write-time across all validation lifecycle documents, generates immutable traceability matrices, and produces audit-ready evidence that reduces CSV cycle time. Its Validate·AI platform integrates with existing QMS environments and supports validated private deployment for organizations with strict data residency requirements.
